Childhood cancer survivor and parent: more likely for women

22 Mar 2016

For women who have survived childhood cancer, the impact of modern chemotherapy regimens on the likelihood of becoming pregnant is generally small, and most have a good chance of conceiving, according to one of the largest studies of its kind.

In contrast, male survivors of childhood cancer are significantly less likely to have children, especially if they are treated with chemotherapy regimens containing high doses of commonly used alkylating drugs and cisplatin.

Fertility can be compromised by several types of chemotherapy

Now that more than 80% of children with cancer are living into adulthood, whether they can have children is a major concern for them. Growing awareness of the adverse effects of radiotherapy has led to the use of more intensive chemotherapy regimens for the treatment of childhood cancers. Previous research has shown that fertility can be compromised by several types of chemotherapy, mainly alkylating drugs.

However, little is known about the dose effects on pregnancy from newer drugs, such as ifosfamide and cisplatin, in survivors of childhood cancer.

The impact of commonly used chemotherapy on pregnancy and livebirth

Dr Eric Chow from the Fred Hutchinson Cancer Research Center, Seattle, USA and colleagues used data from the Childhood Cancer Survivor Study (CCSS) which tracks people who were diagnosed with the most common types of childhood cancer before the age of 21 and treated at 27 institutions across the USA and Canada between 1970 and 1999, and who had survived at least 5 years after diagnosis.

In this study, they examined the impact of various doses of 14 commonly used chemotherapy drugs on pregnancy and livebirth in 10,938 male and female survivors, compared with 3949 siblings.

The study specifically focused on survivors treated with chemotherapy and who did not receive any radiotherapy to the pelvis or the brain.

The findings are consistent with previous studies which have suggested that men who have undergone cancer treatment with these drugs have lower sperm count and reduced testicular volume. In particular:

  • By age 45, 70% of female cancer survivors became pregnant, compared to over 80% of siblings.
  • For male cancer survivors, the figure was 50% compared to 80% for siblings.
  • In male survivors, the likelihood of fathering a child generally decreased as cumulative exposure to alkylating drugs increased.
  • High cumulative doses of several alkylating drugs (cyclophosphamide, ifosfamide, procarbazine) and cisplatin were linked with a significantly reduced likelihood of pregnancy.


Drug effect in men was much bigger

The authors point out that the ifosfamide dose threshold above which male cancer survivors are significantly less likely to father a child is far lower than the dose judged to be high risk in current guidelines (25000 mg/m² vs 60000 mg/m²).

In female survivors, only busulfan and high doses of lomustine were directly linked with lower likelihood of pregnancy. Overall, female survivors were still less likely to conceive compared to siblings but the effect was much smaller compared to men.

However, in women, the difference was more pronounced for those who delayed pregnancy until they were aged 30 or older, possibly because chemotherapy exposure might accelerate the natural depletion of eggs and hasten menopause.

More research is needed to estimate the exact risk

The authors note that their study relied on self-reported pregnancy and livebirth, and that up to a quarter of pregnancies can be unrecognized by women. Although their findings are consistent with others in the field, their study did not account for other factors such as marital or cohabitation status, the intention to conceive or length of time attempting to conceive.

While the total number of survivors in the study is large, the number of patients who were exposed to individual drugs varied significantly.

So, while the overall conclusions of the study are consistent with previous research studies, more research is needed to estimate the exact risk of some less commonly used drugs.

The report enables more accurate personalized counselling

Commenting on the implications of the study, Professor Richard Anderson from the University of Edinburgh, UK and Dr Hamish Wallace from the Royal Hospital for Sick Children, Edinburgh, UK say that this report will enable more accurate counselling of patients about their individual risks.

Responding to the study, Professor Jane Maher, Joint Chief Medical Officer at Macmillan Cancer Support, commented: “People with cancer and their families need to know what options are available to them. Having to have difficult conversations about such important choices, places a huge burden on parents of children going through cancer, as well as adults living with the consequences of their childhood cancer.”

Source: eCancer News

Login to your account

Did you forget your password?